Journal Club #4: Lumateperone: New Antipsychotic for Schizophrenia.

Our fourth journal club will discuss the following recently published article in JAMA Psychiatry:

Efficacy and Safety of Lumateperone for Treatment of Schizophrenia: A Randomized Clinical Trial. JAMA Psychiatry. 2020 Jan 8.

This journal club will be summarized in the following topics/questions:

  1. Lumateperone: Mechanism of action.
  2. Recommended dosage and titration.
  3. Lumateperone 28 mg vs 42 mg vs 84 mg: which one is preferred?
  4. When is the onset of response with Lumateperone?
  5. Lumateperone: Common adverse events.
  6. Association of Lumateperone with EPS, metabolic side effects, QTc prolongation and increase in suicidal ideations?
  7. How Lumateperone compares with other antipsychotics in terms of effect size for reduction in PANSS total symptoms?

One slide from this journal club: Mechanism of Action:

Reference:

  1. Correll CU, Davis RE, Weingart M, Saillard J, O’Gorman C, Kane JM, Lieberman JA, Tamminga CA, Mates S, Vanover KE. Efficacy and Safety of Lumateperone for Treatment of Schizophrenia: A Randomized Clinical Trial. JAMA Psychiatry. 2020 Jan 8. doi: 10.1001/jamapsychiatry.2019.4379. [Epub ahead of print] PubMed PMID: 31913424. (pubmed) (PDF)

Dr. Harvinder Singh

Admin, Psychiatry Education Forum

Subscribe to our Physician’s Guide for Clinical Psychiatry Course:

Related Articles